Rondo Therapeutics Partners with Lilly to Develop CD28 Bispecific Antibodies

Rondo Therapeutics, a biopharmaceutical company focused on developing next-generation T cell-engaging bispecific antibodies, has announced a strategic collaboration and licensing agreement with Eli Lilly and Company. This partnership aims to combine Rondo’s proprietary CD28 co-stimulatory platform with Lilly’s expertise in drug development and commercialization to create novel CD28 bispecific antibodies targeting solid tumors. Under the agreement, Rondo will receive an upfront cash payment, with potential for additional development and commercial milestone payments, as well as tiered royalties on commercial sales. This collaboration highlights the potential for innovative immuno-oncology therapies to offer durable treatment responses for patients with solid tumors and reflects both companies' commitment to advancing cancer therapies. Rondo Therapeutics is backed by notable investors, including SV Health Investors and has a pipeline addressing multiple solid tumors, such as bladder and ovarian cancers.